Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Nanoparticle Therapy Reduces Liver Metastasis Dramatically

By HospiMedica International staff writers
Posted on 29 Mar 2018
Targeting sinusoidal endothelial cells with nanoparticles loaded with micro-RNA elements reduces colon cancer (CC) metastasis to the liver by 80%, according to a new study.

Researchers at the University of the Basque Country (UPV/EHU; Vizcaya, Spain) and the University of Santiago de Compostela (A Coruña, Spain) conducted a study in mice that was designed to examine if restoring the function of altered sinusoidal endothelial cells in the liver could help slow down the CC metastatic process in the liver, since it is known that damaged endothelial cells promote angiogenesis, helping the metastatic tumor mass to grow.

The researchers first induced liver metastasis in mice by using CC cells. More...
From the resulting tumor mass they then extracted endothelial cells. When comparing these endothelial cells with healthy ones, they found that that both proteins and micro-RNA constituents were altered. Using biocomputing tools they then screened and selected the proteins and relevant micro-RNA elements, ending up with a specific micro-RNA, miR-20a, which appears in healthy endothelial cells, but disappears in cells in contact with the tumor.

To restore normal miR-20a levels, the researchers then developed chondroitin sulfate-sorbitan ester nanoparticles, which were conjugated with miR-20a in a delivery system that specifically targets liver sinusoidal endothelial cells. The restoration of normal mir-20a levels induced downregulation of the expression of its protein targets, resulting in a reduction of in vitro cell migration and a reduction of in vivo activation and tumor-infiltrating capacity and ability of the tumor by about 80%. The study was published on March 15, 2018, in the International Journal of Cancer.

“The pathological analysis revealed that, in the cases treated, far fewer new blood vessels had formed inside the tumors. If it is ever used as a treatment, it will be a complementary treatment,” said senior author Iker Badiola, PhD, of the UPV/EHU department of cell biology and histology. “You can't ignore the fact that the metastasis goes on growing 20% and, what is more, at no time are the tumor cells destroyed nor are they attacked directly. The strategy of tackling the metastasis that we have achieved involves limiting the supply of nutrients and oxygen; in other words, we restrict the help.”

Metastasis involves a complex series of steps in which cancer cells leave the original tumor site and migrate to other parts of the body via the bloodstream, via the lymphatic system, or by direct extension. To do so, malignant cells break away from the primary tumor by degrading the surrounding extracellular matrix (ECM), which separates the tumor from adjoining tissues, migrating to other organs. As one of the critical events required for subsequent tumor growth is blood supply, it is therefore thought that angiogenesis inhibitors could prevent or reduce the growth of metastases.

Related Links:
University of the Basque Country
University of Santiago de Compostela

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.